Stock Investing News and Headlines
  • All Technology
  • AI
  • Autonomy
  • B2B Growth
  • Big Data
  • BioTech
  • ClimateTech
  • Consumer Tech
  • Crypto
  • Cybersecurity
  • DevOps
  • Digital Marketing
  • Ecommerce
  • EdTech
  • Enterprise
  • FinTech
  • GovTech
  • Hardware
  • HealthTech
  • HRTech
  • LegalTech
  • Nanotech
  • PropTech
  • Quantum
  • Robotics
  • SaaS
  • SpaceTech
AllNewsDealsSocialBlogsVideosPodcastsDigests

Stock Investing Pulse

EMAIL DIGESTS

Daily

Every morning

Weekly

Tuesday recap

NewsDealsSocialBlogsVideosPodcasts
HomeInvestingStock InvestingNewsThree European Stocks to Buy for Long-Term Growth and Income
Three European Stocks to Buy for Long-Term Growth and Income
Euro StocksStock Investing

Three European Stocks to Buy for Long-Term Growth and Income

•March 9, 2026
0
MoneyWeek – All
MoneyWeek – All•Mar 9, 2026

Why It Matters

These stocks combine robust cash‑flow generation with disciplined capital allocation, positioning them to deliver durable shareholder returns in a low‑growth macro environment. Their dividend sustainability signals financial strength, appealing to income‑focused investors seeking growth exposure.

Key Takeaways

  • •ASML dominates EUV lithography, granting pricing power
  • •Roche maintains dividend growth despite pharma headwinds
  • •Sanpaolo benefits from stronger European banking fundamentals
  • •All three offer sustainable dividends and long‑term growth prospects

Pulse Analysis

ASML’s position as the sole supplier of extreme ultraviolet lithography systems creates a structural moat that few competitors can breach. The technology underpins the most advanced chips required for AI, cloud and high‑performance computing, allowing the Dutch firm to command premium pricing and maintain gross margins above 50%. Investors view this as a catalyst for both earnings expansion and dividend acceleration, especially as chip demand outpaces supply constraints.

Roche’s resilience stems from its diversified therapeutic portfolio and relentless R&D investment, which offsets typical pharmaceutical cyclicality. Recent breakthroughs in oncology and neurology have reinforced its pipeline, while disciplined capital allocation sustains a dividend streak exceeding 30 years. In an industry grappling with patent cliffs and post‑COVID revenue normalization, Roche’s ability to generate consistent cash flow and return capital to shareholders underscores its appeal for long‑term income investors.

Intesa Sanpaolo illustrates the broader revival of European banks, which now operate with higher capital ratios and reduced risk‑weighted assets compared to the crisis era. The bank’s solid retail deposit base and efficient cost structure support stable net‑interest income and a generous dividend yield. Although rate normalization may temper earnings growth, its conservative leverage and limited reliance on capital markets provide a buffer against market volatility, making it a compelling defensive play within a diversified growth‑income portfolio.

Three European stocks to buy for long-term growth and income

Read Original Article
0

Comments

Want to join the conversation?

Loading comments...